U.S. markets closed

Lyell Immunopharma, Inc. (LYEL)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
5.25+0.11 (+2.14%)
At close: 04:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close5.14
Bid4.00 x 1800
Ask5.25 x 2200
Day's Range4.91 - 5.39
52 Week Range4.91 - 19.84
Avg. Volume607,085
Market Cap1.262B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.59
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est23.25
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for LYEL

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Lyell Immunopharma, Inc.
    Daily – Vickers Top Buyers & Sellers for 01/27/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Fair Value
    Economic Moat
    2 days agoArgus Research
View more
  • Benzinga

    FDA Clears Lyell Immunopharma' LYL132 Trial For Solid Tumors

    The FDA has cleared Lyell Immunopharma Inc's (NASDAQ: LYEL) Investigational New Drug (IND) application to initiate a Phase 1 trial for LYL132 in solid tumors. LYL132 is an investigational T-cell receptor (TCR) therapy for patients with solid tumors expressing New York esophageal squamous cell carcinoma 1 (NY-ESO-1). LYL132 incorporates Epi-R, Lyell's epigenetic reprogramming technology, and is under investigation as a potential next-generation enhancement to letetresgene autoleucel (lete-cel), a

  • GlobeNewswire

    Lyell Immunopharma Announces FDA Clearance of IND for LYL132, a T-Cell Receptor Therapy for Solid Tumors Being Developed in Collaboration with GSK

    LYL132 is an NY-ESO-1-targeted TCR therapy that incorporates Epi-R™, Lyell’s novel epigenetic reprogramming technology designed to create populations of T cells with properties of durable stemnessSOUTH SAN FRANCISCO, Calif., Jan. 24, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc., (Nasdaq: LYEL), a T-cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors, announced today that the U.S. Food and Drug Administration (FDA) has cleared an Investigational

  • American City Business Journals

    Superstar biotech execs, scientists, funders launch $3 billion company to 'reverse disease'

    Backed by $3 billion and some of biotech's biggest names, Altos Labs officially emerged from stealth with the ambitious task of reversing disease. The company, which the San Francisco Business Times previously reported had leased space in Redwood City, will be led by former Genentech Inc. chief medical officer Hal Barron, who currently is president of research and development at GlaxoSmithKline plc and held the same position at aging disease research pioneer Calico. Rick Klausner, the former National Cancer Institute chief and founder of a handful of biotech companies, including South San Francisco's Lyell Immunopharma Inc. (NASDAQ: LYEL), is chief scientist, and Grail Inc. founder and former president Hans Bishop will be president.